Archive · 1 Jul 2025
BE and Recbio Partner on HPV9 Vaccine for India
A Chinese company (Recbio) is working with an Indian company (BE) to make a vaccine called HPV9.
This vaccine helps protect against a virus called HPV, which can cause different types of cancer.
The Chinese company will share how to make the vaccine with the Indian company.
The Indian company will sell the vaccine in India and offer it to other markets, with access to tenders.
This helps more people have access to this important vaccine that helps prevent cancer.
Biological E (BE) of India and Jiangsu Recbio Technology of China partnered on an HPV9 vaccine.
Recbio will provide Drug Substance (DS) and technology to formulate, fill, and package the vaccine.
BE will receive exclusive commercialization rights in India and can participate in UNICEF & PAHO tenders.
The technology transfer process has already begun between the two companies.
The HPV9 vaccine protects against nine types of HPV, which can cause several types of cancer.
- Who
- Biological E (BE) and Jiangsu Recbio Technology.
- What
- A licensing cooperation agreement for the HPV9 vaccine.
- When
- The technology transfer process began as of the announcement.
- Where
- India and China, with commercialization primarily in India and other markets.
- Why
- To bring the HPV9 vaccine to India and other countries and improve global health.
- Partner Companies
- Biological E (BE), Jiangsu Recbio Technology
- Vaccine Type
- HPV9 (Recombinant 9-valent HPV)
- Purpose
- Protect against HPV, reducing cancer risk
- Commercialization Rights
- BE holds exclusive rights in India and participation in tenders
- Technology Transfer
- Recbio transfers DS and technology to BE
- Cancer Types Targeted
- Cervical, vulvar, vaginal, anal, oropharyngeal
